Consolato Sergi, Bonnie Chiu, Joseph Feulefack, Fan Shen, Brian Chiu
{"title":"代谢综合征患者与有或无肥胖症的健康人相比，补充白藜芦醇对降低心脏代谢风险因素的作用：利用多国随机对照试验进行的荟萃分析。","authors":"Consolato Sergi, Bonnie Chiu, Joseph Feulefack, Fan Shen, Brian Chiu","doi":"10.5114/amsad.2020.95884","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Resveratrol (RES), a natural polyphenolic compound, has been linked to some beneficial effects against cardiovascular disease (CVD).</p><p><strong>Material and methods: </strong>We conducted a systematic search to conduct a meta-analysis on cardiometabolic risk factors modulated by RES targeting patients with metabolic syndrome (Met-S) and Obese/Healthy (O/H) subjects. The PICO (Patient, Intervention, Comparison, Outcome) research question was: Does RES among patients with Met-S and O/H subjects reduce the cardiometabolic risk? The first group was affected with MetS, which is defined as a clustering of abdominal obesity, dyslipidaemia, hyperglycaemia, and hypertension in a single individual. The second group was composed of 'obese/healthy' individuals, i.e. healthy subjects with or without obesity. We performed a literature search of MEDLINE/ PubMed, Scopus, and Google Scholar for randomised, controlled trials (RCT) that estimated the effects of RES on cardiometabolic risk factors.</p><p><strong>Results: </strong>We found 780 articles, of which 63 original articles and reviews were identified. Data from 17 well-conducted RCT studies, comprising 651 subjects, were extracted for analysis. Overall, RES had a significant influence on Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), resulting in a mean difference of -0.520665 (95% CI: -1.12791; -0.01439; <i>p</i> = 0.00113). In Met-S, RES significantly reduced glucose, low-density lipoprotein-cholesterol (LDL-C), and total cholesterol (T-Chol) as detected by the mean difference of -1.069 (95% CI: -2.107, -0.032; <i>p</i> = 0.043), -0.924 (95% CI: -1.804, -0.043; <i>p</i> = 0.040), and -1.246 (95% CI: -2.314, -0.178; <i>p</i> = 0.022), respectively.</p><p><strong>Conclusions: </strong>Despite some heterogeneity in the populations, RES supplementation seems to improve cardiometabolic health, decreasing some risk factors (HOMA-IR, LDL-C, and T-Chol) associated with CVD.</p>","PeriodicalId":8317,"journal":{"name":"Archives of Medical Sciences. Atherosclerotic Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/c0/AMS-AD-5-40815.PMC7277462.pdf","citationCount":"0","resultStr":"{\"title\":\"Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials.\",\"authors\":\"Consolato Sergi, Bonnie Chiu, Joseph Feulefack, Fan Shen, Brian Chiu\",\"doi\":\"10.5114/amsad.2020.95884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Resveratrol (RES), a natural polyphenolic compound, has been linked to some beneficial effects against cardiovascular disease (CVD).</p><p><strong>Material and methods: </strong>We conducted a systematic search to conduct a meta-analysis on cardiometabolic risk factors modulated by RES targeting patients with metabolic syndrome (Met-S) and Obese/Healthy (O/H) subjects. The PICO (Patient, Intervention, Comparison, Outcome) research question was: Does RES among patients with Met-S and O/H subjects reduce the cardiometabolic risk? The first group was affected with MetS, which is defined as a clustering of abdominal obesity, dyslipidaemia, hyperglycaemia, and hypertension in a single individual. The second group was composed of 'obese/healthy' individuals, i.e. healthy subjects with or without obesity. We performed a literature search of MEDLINE/ PubMed, Scopus, and Google Scholar for randomised, controlled trials (RCT) that estimated the effects of RES on cardiometabolic risk factors.</p><p><strong>Results: </strong>We found 780 articles, of which 63 original articles and reviews were identified. Data from 17 well-conducted RCT studies, comprising 651 subjects, were extracted for analysis. Overall, RES had a significant influence on Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), resulting in a mean difference of -0.520665 (95% CI: -1.12791; -0.01439; <i>p</i> = 0.00113). In Met-S, RES significantly reduced glucose, low-density lipoprotein-cholesterol (LDL-C), and total cholesterol (T-Chol) as detected by the mean difference of -1.069 (95% CI: -2.107, -0.032; <i>p</i> = 0.043), -0.924 (95% CI: -1.804, -0.043; <i>p</i> = 0.040), and -1.246 (95% CI: -2.314, -0.178; <i>p</i> = 0.022), respectively.</p><p><strong>Conclusions: </strong>Despite some heterogeneity in the populations, RES supplementation seems to improve cardiometabolic health, decreasing some risk factors (HOMA-IR, LDL-C, and T-Chol) associated with CVD.</p>\",\"PeriodicalId\":8317,\"journal\":{\"name\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/c0/AMS-AD-5-40815.PMC7277462.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/amsad.2020.95884\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Sciences. Atherosclerotic Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/amsad.2020.95884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
引言白藜芦醇（RES）是一种天然多酚类化合物，对心血管疾病（CVD）有一定的益处：我们进行了一项系统性检索，以代谢综合征（Met-S）患者和肥胖/健康（O/H）受试者为对象，对白藜芦醇调节的心脏代谢风险因素进行荟萃分析。PICO（患者、干预、比较、结果）研究问题是：代谢综合征（Met-S）患者和肥胖/健康（O/H）受试者中的 RES 是否能调节心脏代谢风险因素？代谢综合征（Met-S）患者和肥胖/健康受试者中的 RES 是否能降低心脏代谢风险？第一组是 MetS 患者，MetS 的定义是腹部肥胖、血脂异常、高血糖和高血压在一个人身上的聚集。第二组是 "肥胖/健康 "人群，即有或没有肥胖的健康人。我们在 MEDLINE/PubMed、Scopus 和 Google Scholar 上进行了文献检索，以寻找估计 RES 对心脏代谢风险因素影响的随机对照试验 (RCT)：结果：我们找到了 780 篇文章，其中 63 篇为原创文章和综述。我们从 17 项进行良好的 RCT 研究中提取了 651 名受试者的数据进行分析。总体而言，RES 对体内平衡模型评估-胰岛素抵抗（HOMA-IR）有显著影响，平均差异为-0.520665 (95% CI: -1.12791; -0.01439; p = 0.00113)。在 Met-S 中，RES 能显著降低血糖、低密度脂蛋白胆固醇（LDL-C）和总胆固醇（T-Chol），其平均差异分别为-1.069（95% CI：-2.107，-0.032；p = 0.043）、-0.924（95% CI：-1.804，-0.043；p = 0.040）和-1.246（95% CI：-2.314，-0.178；p = 0.022）：尽管人群中存在一些异质性，但补充 RES 似乎能改善心脏代谢健康，降低与心血管疾病相关的一些风险因素（HOMA-IR、低密度脂蛋白胆固醇和胆固醇）。
Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials.
Introduction: Resveratrol (RES), a natural polyphenolic compound, has been linked to some beneficial effects against cardiovascular disease (CVD).
Material and methods: We conducted a systematic search to conduct a meta-analysis on cardiometabolic risk factors modulated by RES targeting patients with metabolic syndrome (Met-S) and Obese/Healthy (O/H) subjects. The PICO (Patient, Intervention, Comparison, Outcome) research question was: Does RES among patients with Met-S and O/H subjects reduce the cardiometabolic risk? The first group was affected with MetS, which is defined as a clustering of abdominal obesity, dyslipidaemia, hyperglycaemia, and hypertension in a single individual. The second group was composed of 'obese/healthy' individuals, i.e. healthy subjects with or without obesity. We performed a literature search of MEDLINE/ PubMed, Scopus, and Google Scholar for randomised, controlled trials (RCT) that estimated the effects of RES on cardiometabolic risk factors.
Results: We found 780 articles, of which 63 original articles and reviews were identified. Data from 17 well-conducted RCT studies, comprising 651 subjects, were extracted for analysis. Overall, RES had a significant influence on Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), resulting in a mean difference of -0.520665 (95% CI: -1.12791; -0.01439; p = 0.00113). In Met-S, RES significantly reduced glucose, low-density lipoprotein-cholesterol (LDL-C), and total cholesterol (T-Chol) as detected by the mean difference of -1.069 (95% CI: -2.107, -0.032; p = 0.043), -0.924 (95% CI: -1.804, -0.043; p = 0.040), and -1.246 (95% CI: -2.314, -0.178; p = 0.022), respectively.
Conclusions: Despite some heterogeneity in the populations, RES supplementation seems to improve cardiometabolic health, decreasing some risk factors (HOMA-IR, LDL-C, and T-Chol) associated with CVD.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
